Human Medicines European Public Assessment Report (EPAR): Opdivo, Nivolumab, Melanoma,Hodgkin Disease,Carcinoma, Renal Cell,Carcinoma, Non-Small-Cell Lung, Date of Authorisation: 19/06/2015, Revision: 22, Status: Authorised

Case Medical Research
doi 10.31525/cmr-962c37
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Case Journals

Related search

Human Medicines European Public Assessment Report (EPAR): Odomzo, Sonidegib, Carcinoma, Basal Cell, Date of Authorisation: 14/08/2015, Revision: 6, Status: Authorised

Case Medical Research
2019English

Human Medicines European Public Assessment Report (EPAR): Pixuvri, Pixantrone Dimaleate, Lymphoma, Non-Hodgkin, Date of Authorisation: 10/05/2012, Revision: 19, Status: Authorised

Case Medical Research
2019English

Human Medicines European Public Assessment Report (EPAR): PritorPlus, Telmisartan / Hydrochlorothiazide, Hypertension, Date of Authorisation: 22/04/2002, Revision: 33, Status: Authorised

Case Medical Research
2019English

Human Medicines European Public Assessment Report (EPAR): Rebetol, Ribavirin, Hepatitis C, Chronic, Date of Authorisation: 06/05/1999, Revision: 32, Status: Authorised

Case Medical Research
2019English

Human Medicines European Public Assessment Report (EPAR): Erivedge, Vismodegib, Carcinoma, Basal Cell, Date of Authorisation: 12/07/2013, Date of Refusal: 26/04/2013, Revision: 11, Status: Authorised

Case Medical Research
2019English

Human Medicines European Public Assessment Report (EPAR): Farydak, Panobinostat, Multiple Myeloma, Date of Authorisation: 28/08/2015, Revision: 6, Status: Authorised

Case Medical Research
2019English

Human Medicines European Public Assessment Report (EPAR): Lenvima, Lenvatinib, Thyroid Neoplasms, Date of Authorisation: 28/05/2015, Revision: 6, Status: Authorised

Case Medical Research
2019English

Human Medicines European Public Assessment Report (EPAR): Revlimid, Lenalidomide, Multiple Myeloma,Lymphoma, Mantle-Cell,Myelodysplastic Syndromes, Date of Authorisation: 14/06/2007, Revision: 37, Status: Authorised

Case Medical Research
2019English

Human Medicines European Public Assessment Report (EPAR): Mysimba, Naltrexone / Bupropion, Obesity,Overweight, Date of Authorisation: 26/03/2015, Revision: 11, Status: Authorised

Case Medical Research
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy